DCM
ENGN icon

DAFNA Capital Management’s enGene Therapeutics ENGN Stock Holding History

DAFNA Capital Management’s Portfolio ENGN Stock Details ENGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.28M Buy
187,353
+23,708
+14% +$211K 0.29% 55
2025
Q4 		$1.48M Buy
+163,645
New +$1.31M 0.34% 54

Other funds holding ENGN

FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

DAFNA Capital Management's ENGN Position: Q1 2026 in Review

DAFNA Capital Management increased its enGene Therapeutics (ENGN) stake by 14% in Q1 2026, buying an estimated $211K and bringing the position to 187,353 shares worth $1.28M. The position accounts for 0.29% of the portfolio, ranked #55.

DAFNA Capital Management first reported a position in ENGN in Q4 2025 and has held it in 2 quarters since. The position peaked at $1.48M in Q4 2025. 61 funds tracked by Wall St. Rank hold ENGN as of Q1 2026.

  • DAFNA Capital Management held 187,353 shares of enGene Therapeutics worth $1.28M as of Q1 2026.
  • DAFNA Capital Management bought 23,708 enGene Therapeutics shares in Q1 2026, an estimated $211K.
  • enGene Therapeutics made up 0.29% of DAFNA Capital Management's portfolio in Q1 2026, its #55 holding.
  • DAFNA Capital Management first reported a position in enGene Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • DAFNA Capital Management's enGene Therapeutics position peaked at $1.48M in Q4 2025.
  • 61 funds tracked by Wall St. Rank held enGene Therapeutics as of Q1 2026.

Based on DAFNA Capital Management's 13F filing for Q1 2026, filed 15 May 2026.